https://www.selleckchem.com/pr....oducts/Obatoclax-Mes
Although exhaustive efforts to prevent and treat tuberculosis (T was taken the problem still continues due to multi-drug-resistant (MDR) and extensively drug resistant TB (XDR-T. It clearly highlights the urgent need to develop novel "druggable" molecules for the co-infection treatment and strains of MDR-TB and XDR-TB. In this approach a hybrid molecule was created by merging two or more pharmacophores. Active site of targets may be addressed by each of the pharmacophores and proffers the opportunity for selectivity. In a
Aimer
Commentaire
Partagez
